

**Disclaimer:** The content below is for communication purpose only. Our company and its affiliates do not guarantee to anybody that the information below is complete and up-to-date. Our company and its affiliates do not accept any responsibility for any decision made as a result of relying on the information contained herein.

More Details on: [www.microport.com.cn](http://www.microport.com.cn)

Email: [ir@microport.com](mailto:ir@microport.com)  
Tel (021) 38954600  
Fax (021) 50801305

## Feeling Firehawk, Targeting Future Announcement of Results in Firehawk FIM and TARGET I Long Stent Group Research Study

On March 17<sup>th</sup>, 2012, during the workshop “Latest Clinical Trials’ Announcements and First Report on Feature Research” at CIT2012, Run-Lin Gao, MD of Fu Wai Hospital and National Center for Cardiovascular Diseases of China, presented the updated primary endpoint results of randomized controlled clinical trial of Firehawk TARGET I Long Stent Group Research Study. TARGET I Long Stent Group Research Study was performed in 50 eligible patients with average lesion length over 35 mm. The success rate was 100% in all 77 implants. The late loss was  $0.16 \pm 0.16$ mm at 9-month angiographic follow-ups (the follow-up rate is 92%). No death and myocardial infarction (MI) and target vessel revascularization (TVR) were observed through 1-year period of OCT follow-up. The latest data indicates that the efficacy and safety of Firehawk stent are excellent in treatment of ultra-long coronary lesions. The results of the randomized TARGET I Group Research Study will be released at TCT 2012.

## MicroPort’s 1<sup>st</sup> Board Meeting of Year 2012 Held in Shanghai

On March 19, the 1<sup>st</sup> Board Meeting of 2012 of MicroPort Scientific Corporation (the “Company”)

was held at the headquarters in Shanghai. During the meeting, the final results of the Company and its subsidiaries for the year ended 31 December 2011 and final dividend proposal were approved. The Annual Result Announcement for the fiscal year ended 31 December 2011 was released after the meeting.

## Pu Jiang Emerging Medical Technology Forum 2012 Successfully Held in Shanghai

Pu Jiang Emerging Medical Technology Forum 2012 was held successfully in Shanghai from March 24<sup>th</sup> to 25<sup>th</sup>, 2012. This meeting was co-organized by MicroPort and Shanghai Jiao Tong University, and participated jointly by Tsinghua University, Fudan University, Sichuan University, and Beijing Institute of Technology. Academician of Chinese Academy of Sciences, professors, senior researchers as well as executives from nationwide high-tech medical technology corporates were invited. It was the first theme forum focused on emerging medical technologies in China. It was aimed to better promote the transformation of emerging medical technologies to the industrial application and enhance the opportunities for communication and cooperation between industry and academia, and promote the research and industrial development of China's emerging medical technology.

During the two-day meeting, 23 guest speakers

had communicated latest achievements in various medical technology fundamental research and industrial application field, such as nationwide medical information grid system, intelligent healthcare, nanostructured biomaterials technology, biomedical degradable materials and so on. These achievements reflect the future development trend of medical technologies featured with minimally invasive, intelligent, customized, targeted, early-staged, and popularization.



## The Past Three Years Data of Cardiovascular Interventional Treatment Published

The 15<sup>th</sup> China Cardiovascular Intervention Forum, sponsored by Chinese Medical Doctor Association (CMDA), Chinese College of Cardiovascular Physicians (CCCP), Chinese Society of Cardiology, and China Medical Foundation (CMF) was held in Nanning, Guangxi Province from 1 March

to 3 March, 2012. According to statistics, the reported PCI cases of 2011 from 985 hospitals were 332,992, which represent 16.9% increase YOY. The pacemaker implantation in mainland China, excluding implantations conducted by military hospitals, was 42,986 cases in 2011, which represent 10.9% increase YOY. Implantation of ICD (Implantable Cardioverter Defibrillator) reached 1,228 cases and indicated a strong growth of 19.6% YOY. The number of catheter ablation cases was 63,355, presenting 16.1% growth YOY. The total number of the patients who received congenital heart disease treatment in 2011 was 22,967, excluding treatments conducted by military hospitals. Among those 22,967 congenital heart disease treatments, there were 8,089 ASD (Atrial Septal Defect) cases, 4075 PDA (Patent Ductus Arteriosus) cases, 5474 VSD (Ventricular Septal Defect) cases, and 905 PBPV (Percutaneous Balloon Pulmonary Valvuloplasty) cases.

## The Rankings of MicroPort

According to a report from China Market Research Report.com on March 23, MicroPort ranked 10<sup>th</sup> among the Top50 Highest Revenue Shanghai Pharmaceutical Enterprises and 46<sup>th</sup> among the Top100 Highest Profit Chinese Pharmaceutical Enterprises in 2011.